Search Results - "Hermsen, Rick"

Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer by Creemers, Jeroen H A, van der Doelen, Maarten J, van Wilpe, Sandra, Hermsen, Rick, Duiveman-de Boer, Tjitske, Somford, Diederik M, Janssen, Marcel J R, Sedelaar, J P Michiel, Mehra, Niven, Textor, Johannes, Westdorp, Harm

“…Radium-223 improves overall survival (OS) in men with bone metastatic castration-resistant prostate cancer (mCRPC). While the exact mechanism behind this…”
Get full text

99mTc-CXCL8 SPECT to Monitor Disease Activity in Inflammatory Bowel Disease by Aarntzen, Erik H J G, Hermsen, Rick, Drenth, Joost P H, Boerman, Otto C, Oyen, Wim J G

“…Inflammatory bowel diseases (IBDs) are defined as chronic relapsing immune-mediated disorders of the gastrointestinal tract. IBD exacerbations are…”
Get full text

Quantitative and Qualitative Assessment of Urinary Activity of 18F-Flotufolastat-PET/CT in Patients with Prostate Cancer: a Post Hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Studies by Kuo, Phillip H., Hermsen, Rick, Penny, Ross, Postema, Ernst J.

“…Purpose To evaluate the impact of urinary activity on interpretation of 18 F-flotufolastat ( 18 F-rhPSMA-7.3) PET/CT, we conducted a post hoc qualitative and…”
Get full text

Quantitative and Qualitative Assessment of Urinary Activity of 18 F-Flotufolastat-PET/CT in Patients with Prostate Cancer: a Post Hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Studies by Kuo, Phillip H, Hermsen, Rick, Penny, Ross, Postema, Ernst J

“…To evaluate the impact of urinary activity on interpretation of F-flotufolastat ( F-rhPSMA-7.3) PET/CT, we conducted a post hoc qualitative and quantitative…”
Get full text

PD61-02 PREOPERATIVE PSMA PET/CT AS A PREDICTOR OF BIOCHEMICAL PERSISTENCE AND EARLY BIOCHEMICAL RECURRENCE by Baas, Diederik, Schilham, Melline, de Baaij, Joost, Vrijhof, Eric, Hoekstra, Robert, Hermsen, Rick, Somford, Diederik, van Basten, Jean-Paul

Get full text

True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study by Fleming, Mark T, Hermsen, Rick, Purysko, Andrei S, Chau, Albert, Davis, Phillip, Chapin, Brian F, Schuster, David M

“…18F-rhPSMA-7.3 (18F-flotufolastat) is a high-affinity prostate-specific membrane antigen–targeted diagnostic radiopharmaceutical for PET imaging in patients…”
Get full text

True-Positive 18 F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study by Fleming, Mark T, Hermsen, Rick, Purysko, Andrei S, Chau, Albert, Davis, Phillip, Chapin, Brian F, Schuster, David M

“…F-rhPSMA-7.3 ( F-flotufolastat) is a high-affinity prostate-specific membrane antigen-targeted diagnostic radiopharmaceutical for PET imaging in patients with…”
Get full text

Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE) by Surasi, Devaki Shilpa, Eiber, Matthias, Maurer, Tobias, Preston, Mark A., Helfand, Brian T., Josephson, David, Tewari, Ashutosh K., Somford, Diederik M., Rais-Bahrami, Soroush, Koontz, Bridget F., Bostrom, Peter J., Chau, Albert, Davis, Phillip, Schuster, David M., Chapin, Brian F., Allaf, Mohamad, Andriole, Gerald, Avery, Ryan J., Avril, Norbert, Barker, Helen, Belkoff, Laurence, Budäus, Lars, Cher, Michael L., Chisholm, Diane, Covington, Matthew F., Cox, Ian, Ferrandino, Michael, Fleming, Mark T., Franceschi, Dinko, Gardiner, Peter, Gartrell, Benjamin, Gauden, David, Hasa, Ergela, Hermsen, Rick, Horn, Thomas, Iranpour, Pooya, Jacene, Heather, Jayaratna, Isuru, Joshi, Shreyas S., Kay, Matthew, Kostakoglu, Lale, Kuo, Phillip, Lavely, William, Lokuta, Mary, Lowentritt, Benjamin, Miller, Matthew P., Nix, Jeffrey W., Ogan, Kenneth, Penny, Ross, Piert, Morand, Purysko, Andrei, Ravizzini, Gregory, Saltzstein, Daniel, Savir-Baruch, Bital, Siegel, Barry A., Steuber, Thomas, Twardowski, Przemyslaw, Uchio, Edward, Ulaner, Gary A., Wixom, Jenna M., Yoo, Don, Zukotynski, Katherine

“…In this large, diverse population of men with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer, 18F-rhPSMA-7.3 positron emission…”
Get full text

89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer by Verhoeff, Sarah R, van de Donk, Pim P, Aarntzen, Erik HJG, Oosting, Sjoukje F, Brouwers, Adrienne H, Miedema, Iris HC, Voortman, Jens, van Oordt, Willemien C Menke-van der Houven, Boellaard, Ronald, Vriens, Dennis, Slingerland, Marije, Hermsen, Rick, van Engen-Grunsven, Ilse, Heskamp, Sandra, van Herpen, Carla ML

“…In this PD-L1 ImagiNg to prediCt durvalumab treatment response in SCCHN (PINCH) study, we performed 89Zr-DFO-durvalumab (anti–PD-L1 [programmed death ligand…”
Get full text

Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia’s Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578–80 by Schilham, Melline G.M., Rijpkema, Mark, Scheenen, Tom, Hermsen, Rick, Barentsz, Jelle O., Sedelaar, J.P.Michiel, Kusters-Vandevelde, Heidi, Kerkmeijer, Linda G.W., Somford, Diederik M., Gotthardt, Martin

Get full text

How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come by Schilham, Melline G.M., Rijpkema, Mark, Scheenen, Tom, Hermsen, Rick, Barentsz, Jelle O., Michiel Sedelaar, J.P., Kusters-Vandevelde, Heidi, Kerkmeijer, Linda G.W., Somford, Diederik M., Gotthardt, Martin

“…In recent years, clinical use of novel advanced imaging modalities in prostate cancer detection, staging, and therapy has intensified and is currently…”
Get full text

Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial by Schilham, Melline G M, Somford, Diederik M, Küsters-Vandevelde, Heidi V N, Hermsen, Rick, van Basten, Jean Paul A, Hoekstra, Robert J, Scheenen, Tom W J, Gotthardt, Martin, Sedelaar, J P Michiel, Rijpkema, Mark

“…Prostate-specific membrane antigen (PSMA)-targeted radioguided surgery (RGS) aims to optimize the peroperative detection and removal of PSMA-avid lymph node…”
Get full text

Immunohistochemical and histopathological validation of 18 F-PSMA-1007 PET/CT for intraprostatic cancerous lesions by Heetman, Joris G, Hermsen, Rick, Exterkate, Leonie, Küsters-Vandevelde, Heidi V N, Brouwer, Lenneke J M, Somford, Diederik M, van den Bergh, Roderick C N, van Basten, Jean-Paul A

“…Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer (PCa). In this study, we aim to immunohistochemically and histopathological…”
Get full text

The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223 Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients by Bosch, Dianne, van der Velden, Kim J M, Oving, Irma M, Wyndaele, Dirk N J, Weijs, Leo E, van Schelven, W Dick, Oyen, Wim J G, Te Beek, Erik T, van de Luijtgaarden, Addy C M, Somford, Diederik M, Nagarajah, James, Hermsen, Rick, Mehra, Niven, Gerritsen, Winald R, van der Doelen, Maarten J, van Oort, Inge M

“…Imaging before Ra-dichloride ( Ra) therapy is crucial for selecting metastatic castration-resistant prostate cancer (mCRPC) patients with bone-only disease…”
Get full text

The association of quantitative PSMA PET parameters with pathologic ISUP grade: an international multicenter analysis by Soeterik, Timo F W, Heetman, Joris G, Hermsen, Rick, Wever, Lieke, Lavalaye, Jules, Vinken, Maarten, Bahler, Clinton D, Yong, Courtney, Tann, Mark, Kesch, Claudia, Seifert, Robert, Telli, Tugce, Chiu, Peter Ka-Fung, Wu, Kwan Kit, Zattoni, Fabio, Evangelista, Laura, Segalla, Emma, Barone, Antonio, Ceci, Francesco, Rajwa, Pawel, Marra, Giancarlo, Mazzone, Elio, Van Basten, Jean-Paul A, Van Melick, Harm H E, Van den Bergh, Roderick C N, Gandaglia, Giorgio

“…To assess if PSMA PET quantitative parameters are associated with pathologic ISUP grade group (GG) and upgrading/downgrading. PCa patients undergoing radical…”
Get full text

Immunohistochemical and histopathological validation of 18F‐PSMA‐1007 PET/CT for intraprostatic cancerous lesions by Heetman, Joris G., Hermsen, Rick, Exterkate, Leonie, Küsters‐Vandevelde, Heidi V. N., Brouwer, Lenneke J. M., Somford, Diederik M., Bergh, Roderick C. N., Basten, Jean‐Paul A.

“…Introduction Prostate‐specific membrane antigen (PSMA) is overexpressed in prostate cancer (PCa). In this study, we aim to immunohistochemically and…”
Get full text

The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients by Bosch, Dianne, van der Velden, Kim JM, Oving, Irma M, Wyndaele, Dirk NJ, Weijs, Leo E, van Schelven, W Dick, Oyen, Wim JG, te Beek, Erik T, van de Luijtgaarden, Addy CM, Somford, Diederik M, Nagarajah, James, Hermsen, Rick, Mehra, Niven, Gerritsen, Winald R, van der Doelen, Maarten J, van Oort, Inge M

“…Imaging before 223Ra-dichloride (223Ra) therapy is crucial for selecting metastatic castration-resistant prostate cancer (mCRPC) patients with bone-only…”
Get full text

Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference by Hermsen, Rick, Wedick, Esmée B. C., Vinken, Maarten J. M., van Kalmthout, Ludwike W. M., Küsters-Vandevelde, Heidi V. N., Wijers, Charlotte H. W., Somford, Diederik M., van Basten, Jean-Paul A.

“…Purpose Fluorine-18 ( 18 F) prostate–specific membrane antigen (PSMA) 1007 ( 18 F-PSMA-1007) is a radiotracer used in prostate cancer (PCa) staging. So far, no…”
Get full text

Diagnostic Performance and Safety of 18 F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT) by Jani, Ashesh B, Ravizzini, Gregory C, Gartrell, Benjamin A, Siegel, Barry A, Twardowski, Przemyslaw, Saltzstein, Daniel, Fleming, Mark T, Chau, Albert, Davis, Phillip, Chapin, Brian F, Schuster, David M

“…SPOTLIGHT (NCT04186845) evaluated diagnostic performance and safety of radiohybrid F-rhPSMA-7.3, a novel high-affinity positron emission tomography…”
Get full text

89 Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer by Verhoeff, Sarah R, van de Donk, Pim P, Aarntzen, Erik H J G, Oosting, Sjoukje F, Brouwers, Adrienne H, Miedema, Iris H C, Voortman, Jens, Menke-van der Houven van Oordt, Willemien C, Boellaard, Ronald, Vriens, Dennis, Slingerland, Marije, Hermsen, Rick, Grunsven, Ilse van Engen-van, Heskamp, Sandra, van Herpen, Carla M L

“…In this PD-L1 ImagiNg to prediCt durvalumab treatment response in SCCHN (PINCH) study, we performed Zr-DFO-durvalumab (anti-PD-L1 [programmed death ligand 1])…”
Get full text